MORRIS PLAINS, N.J., Aug. 1, 2008 (PRIME NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, announced today that epratuzumab in combination with chemotherapy produced promising results in children with relapsed acute lymphoblastic leukemia (ALL), including 9 patients achieving a complete response. Results from this study were published in the August 1, 2008 issue of the Journal of Clinical Oncology, entitled "Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study," by E.A. Raetz, M.S. Cairo, M.J. Borowitz, S.M. Blaney, M.D. Krailo, T.A. Leil, J.M. Reid, D.M. Goldenberg, W.A. Wegener, W.L. Carroll and P.C. Adamson.
